Docket Number:28A-1031014
Inventor:Shie-Liang Hsieh, Ming-Ting Huang, Yung-Chi Chang
IP Status:TW I569804、US 10172919 B2
Abstract:
A method of treating influenza A virus (IAV) infection by a fusion protein. Accordingto some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.
Fields of Application:
Drug discovery
Advantages when compared to the existing technologies:
Macrophages are the potential therapeutic targets to attenuate IAV-induced pulmonary inflammation, and DcR3 fusion proteins are promising therapeutic agents to protect host from IAV-induced lethality.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
